{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:08:41Z","timestamp":1792202921472,"version":"4.4.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.jaad.2013.05.003","type":"journal-article","created":{"date-parts":[[2013,7,15]],"date-time":"2013-07-15T23:11:43Z","timestamp":1373929903000},"page":"173.e1-173.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":218,"title":["Toxic epidermal necrolysis"],"prefix":"10.1016","volume":"69","author":[{"given":"Robert A.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick H.","family":"McDonough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2013.05.003_bib1","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions","volume":"353","author":"Rzany","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2013.05.003_bib2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2165\/00002018-200528100-00008","article-title":"Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors","volume":"28","author":"La Grenade","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2013.05.003_bib3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.burns.2009.06.213","article-title":"Toxic epidermal necrolysis (Lyell\u2019s disease)","volume":"36","author":"Lissia","year":"2010","journal-title":"Burns"},{"key":"10.1016\/j.jaad.2013.05.003_bib4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaad.2013.05.003_bib5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/sim.4780100408","article-title":"Using a claims database to investigate drug-induced Stevens-Johnson syndrome","volume":"10","author":"Strom","year":"1991","journal-title":"Stat Med"},{"key":"10.1016\/j.jaad.2013.05.003_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archderm.1990.01670250049006","article-title":"The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients","volume":"126","author":"Chan","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib7","first-page":"1039","article-title":"Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985","volume":"23","author":"Roujeau","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/archderm.1991.01680050083008","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany","volume":"127","author":"Sch\u00f6pf","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib9","series-title":"Dermatology","first-page":"323","article-title":"Toxic epidermal necrolysis","author":"French","year":"2003"},{"key":"10.1016\/j.jaad.2013.05.003_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/11593240-000000000-00000","article-title":"Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study","volume":"12","author":"Mittmann","year":"2012","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-4632.2012.05743.x","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries","volume":"52","author":"Saka","year":"2013","journal-title":"Int J Dermatol"},{"issue":"5 suppl","key":"10.1016\/j.jaad.2013.05.003_bib12","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.jaad.2005.09.021","article-title":"Toxic epidermal necrolysis in a mother and fetus","volume":"55","author":"Rodriguez","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/0019-5154.77546","article-title":"Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis over a period of 10 years","volume":"56","author":"Sanmarkan","year":"2011","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/ageing\/22.6.450","article-title":"Toxic epidermal necrolysis (Lyell syndrome) in 77 elderly patients","volume":"22","author":"Bastuji-Garin","year":"1993","journal-title":"Age Ageing"},{"key":"10.1016\/j.jaad.2013.05.003_bib15","first-page":"231","article-title":"L\u2019erythrodermie bulleuses avec epidermolyse","volume":"37","author":"Debre","year":"1939","journal-title":"Bull Soc Pediatr"},{"key":"10.1016\/j.jaad.2013.05.003_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2133.1956.tb12766.x","article-title":"Toxic epidermal necrolysis: an eruption resembling scalding of the skin","volume":"68","author":"Lyell","year":"1956","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2133.1979.tb03571.x","article-title":"Toxic epidermal necrolysis (the scalded skin syndrome): a reappraisal","volume":"100","author":"Lyell","year":"1979","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/archpedi.1922.04120120077005","article-title":"A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children","volume":"24","author":"Stevens","year":"1922","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.jaad.2013.05.003_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/path.1700680209","article-title":"Erythema multiforme exudativum major (Stevens-Johnson syndrome)","volume":"68","author":"Alexander","year":"1954","journal-title":"J Path Bact"},{"key":"10.1016\/j.jaad.2013.05.003_bib20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0190-9622(83)80003-6","article-title":"Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes","volume":"8","author":"Huff","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib22","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1111\/1523-1747.ep12388434","article-title":"The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification","volume":"102","author":"Roujeau","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib23","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1346-8138.1997.tb02524.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme","volume":"24","author":"Roujeau","year":"1997","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib24","first-page":"1883","article-title":"Erythema multiforme","volume":"74","author":"Lamoreux","year":"2006","journal-title":"Am Fam Phys"},{"key":"10.1016\/j.jaad.2013.05.003_bib25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archderm.1995.01690170041005","article-title":"Erythema multiforme with mucous membrane involvement and Stevens\u2013Johnson syndrome are clinically different disorders with distinct causes","volume":"131","author":"Assier","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib26","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-4632.2011.05348.x","article-title":"Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist","volume":"51","author":"Sokumbi","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib27","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Mockenhaupt","year":"2001","journal-title":"Exp Rev Clin Immunol"},{"key":"10.1016\/j.jaad.2013.05.003_bib28","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2013.05.003_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaad.2013.05.003_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1081-1206(10)61112-X","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature","volume":"94","author":"Letko","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2013.05.003_bib31","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/archderm.1975.01630210051002","article-title":"Toxic epidermal necrolysis. A review of 75 cases in children","volume":"111","author":"Rasmussen","year":"1975","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib32","first-page":"123","article-title":"Toxic epidermal necrolysis","volume":"59","author":"Schwartz","year":"1997","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2013.05.003_bib33","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis: clinical findings and prognostic factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib34","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0190-9622(85)70207-1","article-title":"Acute disseminated epidermal necrolysis types 1, 2 and 3: study of 60 cases","volume":"13","author":"Ruiz-Maldonado","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0190-9622(91)70176-3","article-title":"Toxic epidermal necrolysis: a review","volume":"25","author":"Avakian","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1067\/mjd.2003.39","article-title":"History and clinical significance of mechanical symptoms in blistering dermatoses: a reappraisal","volume":"48","author":"Grando","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/archderm.1953.01540090096013","article-title":"Nikolsky sign; page from \u201cnotable contributors to the knowledge of dermatology\u201d","volume":"68","author":"Goodman","year":"1953","journal-title":"AMA Arch Derm Syphilol"},{"key":"10.1016\/j.jaad.2013.05.003_bib38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/00015550510038232","article-title":"Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients","volume":"85","author":"Kim","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2013.05.003_bib39","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2230.2010.03826.x","article-title":"Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre","volume":"35","author":"Rajaratnam","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaad.2006.04.048","article-title":"Toxic epidermal necrolysis","volume":"56","author":"Pereira","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib41","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0190-9622(96)90297-2","article-title":"Renal involvement in toxic epidermal necrolysis","volume":"34","author":"Blum","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib42","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1007\/BF01296123","article-title":"Ileal involvement in toxic epidermal necrolysis (Lyell syndrome)","volume":"38","author":"Michel","year":"1993","journal-title":"Digest Dis Sci"},{"key":"10.1016\/j.jaad.2013.05.003_bib43","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/thx.49.9.935","article-title":"Bronchial obstruction due to respiratory mucosal sloughing in toxic epidermal necrolysis","volume":"49","author":"Dasgupta","year":"1994","journal-title":"Thorax"},{"key":"10.1016\/j.jaad.2013.05.003_bib44","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1365-2044.1995.tb06144.x","article-title":"Toxic epidermal necrolysis with adult respiratory distress syndrome","volume":"50","author":"Wallis","year":"1995","journal-title":"Anaesthesia"},{"key":"10.1016\/j.jaad.2013.05.003_bib45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0736-4679(89)90412-5","article-title":"Toxic epidermal necrolysis","volume":"7","author":"Dolan","year":"1989","journal-title":"J Emerg Med"},{"key":"10.1016\/j.jaad.2013.05.003_bib46","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1159\/000195632","article-title":"Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"29","author":"Hung","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jaad.2013.05.003_bib47","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2332\/allergolint.O-07-483","article-title":"Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006","volume":"56","author":"Yamane","year":"2007","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaad.2013.05.003_bib48","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s001340050492","article-title":"Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study","volume":"23","author":"Lebargy","year":"1997","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jaad.2013.05.003_bib49","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2133.1986.tb02806.x","article-title":"Haemtological disturbances and immune mechanisms in toxic epidermal necrolysis","volume":"114","author":"Goens","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib50","first-page":"59","article-title":"Toxic epidermal necrolysis following morbilli-parotitis-rubella vaccination","volume":"13","author":"Dobrosavlijevic","year":"1999","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2013.05.003_bib51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00006454-200102000-00022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system","volume":"20","author":"Ball","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jaad.2013.05.003_bib52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/adc.53.1.38","article-title":"Mycoplasma pneumoniae infections in children","volume":"53","author":"Stevens","year":"1978","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaad.2013.05.003_bib53","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02113442","article-title":"Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection","volume":"14","author":"Fournier","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jaad.2013.05.003_bib54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000322963","article-title":"A rare case of toxic epidermal necrolysis with unexpected fever resulting from dengue virus","volume":"2","author":"Grieb","year":"2010","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib55","doi-asserted-by":"crossref","first-page":"e2011004","DOI":"10.4084\/mjhid.2011.004","article-title":"Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis","volume":"3","author":"Khalaf","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.jaad.2013.05.003_bib56","first-page":"837","article-title":"Case of fatal toxic epidermal necrolysis due to cardiac catheterization dye","volume":"9","author":"Baldwin","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib57","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.gie.2005.06.034","article-title":"A case of toxic epidermal necrolysis with involvement of the GI tract after systemic contrast agent application at cardiac catheterization","volume":"62","author":"Garza","year":"2005","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jaad.2013.05.003_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib59","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1001\/archderm.1987.01660330077013","article-title":"The culprit drugs in 87 cases toxic epidermal necrolysis\u00a0(Lyell\u2019s syndrome)","volume":"123","author":"Guillaume","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib60","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharm Ther"},{"key":"10.1016\/j.jaad.2013.05.003_bib61","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2013.05.003_bib62","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2002.01622.x","article-title":"Drug Specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis","volume":"118","author":"Nassif","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000083947","article-title":"Novel treatment for drug-induced toxic epidermal necrolysis (Lyell's syndrome)","volume":"136","author":"Paquet","year":"2005","journal-title":"Int Arch Allerg Immunol"},{"key":"10.1016\/j.jaad.2013.05.003_bib64","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archderm.1991.01680050095011","article-title":"T-cell subsets in drug-induced toxic epidermal necrolysis. Possible pathogenic mechanism induced by CD8-positive T cells","volume":"127","author":"Miyauchi","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib65","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2133.2005.07023.x","article-title":"The CD40\/CD40L system is expressed in the\u00a0cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome\/toxic epidermal necrolysis spectrum","volume":"154","author":"Caproni","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib66","series-title":"Hematology: basic principles and practice","first-page":"95","article-title":"Overview and compartmentalization of the immune system","author":"Powell","year":"2008"},{"key":"10.1016\/j.jaad.2013.05.003_bib67","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/j.1365-2133.2006.07211.x","article-title":"Elevated circulating CD40 ligand in patients with erythema multiforme and Stevens-Johnson syndrome\/toxic epidermal necrolysis spectrum","volume":"154","author":"Caproni","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib68","series-title":"Kuby immunology","year":"2007"},{"key":"10.1016\/j.jaad.2013.05.003_bib69","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2133.2006.07398.x","article-title":"Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"155","author":"Caproni","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib70","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00000372-200010000-00005","article-title":"Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis","volume":"22","author":"Paquet","year":"2000","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2013.05.003_bib71","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2133.2011.10649.x","article-title":"Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"166","author":"Tohyama","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib72","first-page":"376","article-title":"Immunological mechanisms of epidermal damage in toxic epidermal necrolysis","volume":"12","author":"Tohyama","year":"2012","journal-title":"Drug Allergy"},{"key":"10.1016\/j.jaad.2013.05.003_bib73","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/archderm.141.6.683","article-title":"Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis","volume":"141","author":"Quinn","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib74","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaci.2012.09.014","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients","volume":"131","author":"Saito","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"3 suppl","key":"10.1016\/j.jaad.2013.05.003_bib75","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.jaci.2010.11.048","article-title":"Immune pathomechanism of drug hypersensitivity reactions","volume":"127","author":"Pichler","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2013.05.003_bib76","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2009.10.031","article-title":"Stimulation of human T cells with sulfonamides and sulfonamide metabolites","volume":"125","author":"Castrejon","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2013.05.003_bib77","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.4049\/jimmunol.164.12.6647","article-title":"Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals","volume":"164","author":"Schnyder","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2013.05.003_bib78","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tox.2003.12.008","article-title":"A chemically inert drug can stimulate T cells in\u00a0vitro by their T cell receptor in non-sensitized individuals","volume":"197","author":"Engler","year":"2004","journal-title":"Toxicology"},{"key":"10.1016\/j.jaad.2013.05.003_bib79","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.immuni.2008.04.020","article-title":"Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of systemic drug hypersensitivity","volume":"28","author":"Chessman","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.jaad.2013.05.003_bib80","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2013.05.003_bib81","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaad.2013.05.003_bib82","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/pgs.09.162","article-title":"Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese","volume":"11","author":"Hung","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaad.2013.05.003_bib83","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2013.05.003_bib84","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaad.2013.05.003_bib85","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1528-1167.2010.02533.x","article-title":"Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population","volume":"51","author":"Tassaneeyakul","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaad.2013.05.003_bib86","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-4632.2010.04745.x","article-title":"Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian populations","volume":"50","author":"Chang","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib87","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4103\/0378-6323.57718","article-title":"Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians","volume":"75","author":"Mehta","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2013.05.003_bib88","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaad.2013.05.003_bib89","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1346-8138.2008.00548.x","article-title":"Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients","volume":"35","author":"Kashiwagi","year":"2008","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib90","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eplepsyres.2011.08.010","article-title":"Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Korea","volume":"97","author":"Kim","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jaad.2013.05.003_bib91","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A marker for Stevens-Johnson syndrome\u2026: ethnicity matters","volume":"6","author":"Lonjou","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaad.2013.05.003_bib92","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaad.2013.05.003_bib93","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2013.05.003_bib94","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","article-title":"Genetic variations in HLA-B region and hypersensitivity reactions to abacavir","volume":"359","author":"Hetherington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2013.05.003_bib95","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2013.05.003_bib96","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2007.06.017","article-title":"HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome","volume":"120","author":"Yang","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2013.05.003_bib97","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2133.1996.tb06976.x","article-title":"Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis","volume":"134","author":"Paul","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib98","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2013.05.003_bib99","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1399-0039.2008.01218.x","article-title":"Biology and clinical relevance of granulysin","volume":"73","author":"Krensky","year":"2009","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jaad.2013.05.003_bib100","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib101","doi-asserted-by":"crossref","first-page":"514","DOI":"10.7326\/0003-4819-151-7-200910060-00016","article-title":"Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome","volume":"151","author":"Abe","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2013.05.003_bib102","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jdermsci.2008.06.003","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases","volume":"52","author":"Abe","year":"2008","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2013.05.003_bib103","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0092-8674(00)81874-7","article-title":"Apoptosis by death factor","volume":"88","author":"Nagata","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2013.05.003_bib104","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jaad.2013.05.003_bib105","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2013.05.003_bib106","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaci.2008.06.013","article-title":"Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment","volume":"122","author":"Murata","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2013.05.003_bib107","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/sj.jid.5700648","article-title":"Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthems","volume":"127","author":"Stur","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib108","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/377446a0","article-title":"Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B","volume":"377","author":"Darmon","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2013.05.003_bib109","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2013.05.003_bib110","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1001\/archdermatol.2011.104","article-title":"Endothelial damage in all types of T-lymphocyte-mediated drug-induced eruptions","volume":"147","author":"Verneuil","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib111","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1365-2133.2009.09357.x","article-title":"Endothelial cell apoptosis in severe drug-induced bullous eruptions","volume":"161","author":"Verneuil","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib112","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archderm.1994.01690050073012","article-title":"Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis","volume":"130","author":"Paquet","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib113","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.2005.06721.x","article-title":"Toxic epidermal necrolysis: current evidence, practical management and future directions","volume":"153","author":"Chave","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib114","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2013.05.003_bib115","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0014-2999(98)00274-X","article-title":"Nitric oxide and its role in apoptosis","volume":"351","author":"Brune","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jaad.2013.05.003_bib116","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1046\/j.1523-1747.2000.00816.x","article-title":"Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"114","author":"Lerner","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib117","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/jid.2012.330","article-title":"TNF-\u03b1 and IFN-\u03b3 are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis","volume":"133","author":"Viard-Leveugle","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.05.003_bib118","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11532540-000000000-00000","article-title":"New insights in toxic epidermal necrolysis (Lyell\u2019s syndrome): clinical considerations, pathobiology and targeted treatments revisited","volume":"33","author":"Paquet","year":"2010","journal-title":"Drug Saf"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213005100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213005100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:28:15Z","timestamp":1759271295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962213005100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":118,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0190962213005100"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2013.05.003","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxic epidermal necrolysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2013.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}